Former Alexion execs and Rallybio co-founders Martin Mackay, Steve Uden and Jeffrey Fryer closed a series B venture capital round to take three candidates into the clinic and acquire additional programs.
[Rallybio] accomplished a lot in the two years since it closed a $37m series A venture capital round, and now the rare disease-focused start-up has raised a $145m series B round to take its first three therapeutic candidates into the clinic in 2020 and 2021, as well as to acquire additional programs.
New Haven, CT-based Rallybio does not have a technology platform for developing novel drug candidates, but it does have three...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
